1
|
Kutscher L, Batora N, Okonechnikov K, Clark J, Vouri M, Rijn SV, Gearhart M, Orr B, Korshunov A, Kool M, Bardwell V, Pfister SM, Northcott PA, Kawauchi D. MEDU-21. LOSS OF THE TRANSCRIPTIONAL CO-REPRESSOR BCOR LEADS TO OVEREXPRESSION OF THE GROWTH FACTOR IGF2 AND SHH MEDULLOBLASTOMA TUMOR FORMATION. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz036.180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Lena Kutscher
- Hopp-Children’s Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Nadja Batora
- Hopp-Children’s Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Konstantin Okonechnikov
- Hopp-Children’s Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Jessica Clark
- Hopp-Children’s Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Mikaella Vouri
- Hopp-Children’s Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Sjoerd van Rijn
- Hopp-Children’s Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | | | - Brent Orr
- St. Jude Children’s Research Hospital, Memphis, TN, USA
| | - Andrey Korshunov
- Heidelberg University Hospital, Heidelberg, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Marcel Kool
- Hopp-Children’s Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | | | - Stefan M Pfister
- Hopp-Children’s Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | | | - Daisuke Kawauchi
- Hopp-Children’s Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| |
Collapse
|
2
|
Kawauchi D, Clark J, Okonechnikov K, Batora N, Vouri M, van Rijn S, Gearhart M, Orr B, Korshunov A, Kool M, Bardwell V, Pfister S, Northcott P. MBRS-07. BCOR LOSS IMPACTS SHH MEDULLOBLASTOMA FORMATION VIA TRANSCRIPTIONAL UP-REGULATION OF Igf2. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy059.453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Daisuke Kawauchi
- Hopp-Children’s Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, BW, Germany
- German Cancer Research Center (DKFZ), Heidelberg, BW, Germany
| | - Jessica Clark
- Hopp-Children’s Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, BW, Germany
- German Cancer Research Center (DKFZ), Heidelberg, BW, Germany
| | - Konstantin Okonechnikov
- Hopp-Children’s Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, BW, Germany
- German Cancer Research Center (DKFZ), Heidelberg, BW, Germany
| | - Nadja Batora
- Hopp-Children’s Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, BW, Germany
- German Cancer Research Center (DKFZ), Heidelberg, BW, Germany
| | - Mikaella Vouri
- Hopp-Children’s Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, BW, Germany
- German Cancer Research Center (DKFZ), Heidelberg, BW, Germany
| | - Sjoerd van Rijn
- Hopp-Children’s Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, BW, Germany
- German Cancer Research Center (DKFZ), Heidelberg, BW, Germany
| | | | - Brent Orr
- St. Jude Children’s Research Hospital, Memphis, TN, USA
| | - Andrey Korshunov
- German Cancer Research Center (DKFZ), Heidelberg, BW, Germany
- Heidelberg University Hospital, Heidelberg, BW, Germany
| | - Marcel Kool
- Hopp-Children’s Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, BW, Germany
- German Cancer Research Center (DKFZ), Heidelberg, BW, Germany
| | | | - Stefan Pfister
- Hopp-Children’s Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, BW, Germany
- German Cancer Research Center (DKFZ), Heidelberg, BW, Germany
| | | |
Collapse
|
3
|
Bardwell V, Corcoran C, Gearhart M, Zhang T. Loss of function of the Polycomb repressor complex (PRC1.1) protein, BCOR, in the placenta results in disruption of trophectoderm derived cell fates, IUGR and death. Placenta 2016. [DOI: 10.1016/j.placenta.2016.06.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
4
|
Lefebure MP, Tothill R, Li J, Matthews G, Shortt J, Hawkins E, Kruse E, Doyle M, Poortinga G, Hannan R, Bardwell V, Gearhart M, Johnstone RW. Abstract 449: Exome sequencing reveals Bcl6 co-repressor (Bcor) as a frequently mutated tumor suppressor gene in Eμ-Myc lymphoma. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Genetically-engineered mouse models offer controlled and reproducible systems in which to study the genetics of cancer development. We have used massively-parallel sequencing to provide a comprehensive analysis of the step-wise progression of cancer in the highly tractable Eμ-Myc mouse model. The Eμ-Myc mouse has been engineered to harbor a t(8;14) translocation juxtaposing the IgH enhancer to the proto-oncogene Myc, a lesion frequently observed in mature B-cell malignancies. Eμ-Myc mice develop spontaneous Burkitt-like B-cell leukemia/lymphoma with 100% penetrance through predicable premalignant to malignant progression phases. Malignant progression ostensibly occurs as a result of secondary somatic mutations that co-operate with Myc. Despite common perception that the majority of tumors can be explained by disruption of the archetypal Cdkn2a and Trp53 tumor suppressor axis, in more than half of spontaneous Eμ-Myc tumors harbor secondary mutations that remain unknown. We hypothesize that the identification of genes that cooperate with Myc could therefore yield not only new biological insight into oncogenic pathways involved in B-cell lymphomagenesis but also improve therapy for patients in the future.
We applied exome-sequencing to a cohort of 18 spontaneous murine Eμ-Myc lymphomas to determine novel somatic driver mutations capable of cooperating with Myc. In addition to exome-sequencing, we harvested blood samples at 2-week intervals throughout the premalignant to malignant phases to allow a temporal analysis of mutations that were detected at end-stage. End-stage tumors were found to be heterogeneous in nature, ranging from 11 to 36 single-base mutations, deletions or insertions. The screen identified genes previously described to be mutated in Eμ-Myc lymphoma (Trp53, Cdkn2a, Kras and Nras). Interestingly, concurrent mutations in known cancer genes were evident in clonal tumors from the sequenced cohort with, for example, a Cdkn2a deletion co-occurring with an activating Kras mutation. In addition to these mutations, we identified novel protein-truncating mutations in Bcl6 co-repressor (Bcor), which has not previously been described in Eμ-Myc lymphoma. Bcor truncating mutations were present at a high frequency, occurring in 3 out of 18 samples. RNAi mediated knockdown of Bcor in Eμ-Myc fetal liver hematopoietic stem cells reconstituted into lethally irradiated congenic recipient mice accelerated lymphomagenesis, validating Bcor as a tumor suppressor gene in this model.
BCOR loss-of-function mutations have recently been identified in human cancers suggesting that BCOR acts as a tumor-suppressor in a wide range of malignancies. Given that Bcor mutations frequently occur in the Eμ-Myc lymphoma, we hypothesize that Bcor is critically important for B-cell development and that its disruption can induce malignancy in co-operation with other potent oncogenes such as Myc.
Citation Format: Marcus P. Lefebure, Richard Tothill, Jason Li, Geoff Matthews, Jake Shortt, Edwin Hawkins, Elizabeth Kruse, Maria Doyle, Gretchen Poortinga, Ross Hannan, Vivian Bardwell, Micah Gearhart, Ricky W. Johnstone. Exome sequencing reveals Bcl6 co-repressor (Bcor) as a frequently mutated tumor suppressor gene in Eμ-Myc lymphoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 449. doi:10.1158/1538-7445.AM2014-449
Collapse
Affiliation(s)
| | | | - Jason Li
- 1Peter MacCallum Cancer Centre, Melbourne, Australia
| | | | - Jake Shortt
- 1Peter MacCallum Cancer Centre, Melbourne, Australia
| | | | | | - Maria Doyle
- 1Peter MacCallum Cancer Centre, Melbourne, Australia
| | | | - Ross Hannan
- 1Peter MacCallum Cancer Centre, Melbourne, Australia
| | | | | | | |
Collapse
|
5
|
Schneider CR, Buell JF, Gearhart M, Thomas M, Hanaway MJ, Rudich SM, Woodle ES. Methicillin-resistant Staphylococcus aureus infection in liver transplantation: a matched controlled study. Transplant Proc 2005; 37:1243-4. [PMID: 15848683 DOI: 10.1016/j.transproceed.2005.01.059] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
UNLABELLED The purpose of this study was to evaluate the clinical impact of methicillin-resistant Staphylococcus aureus (MRSA) infections on transplant recipients. METHODS Liver and kidney recipients with MRSA infections were retrospectively identified and compared to an age, gender, UNOS status, organ transplanted, and transplant date matched (2:1) non-MRSA-infected recipient control group. All MRSA infections were initially treated with vancomycin, and four (33%) liver recipients were converted to linezolid therapy after failing to improve with vancomycin. RESULTS The overall MRSA infection incidence was 1.4% (24/1770) with MRSA more common in liver (3.75%; 12/320) than kidney transplants (0.8%; 12/1450) (P < .001). The most common sites of MRSA infection were blood (42%), lung (38%), and abdomen (29%). The MRSA group had a greater percentage of prior antibiotic usage (79% vs 40%; P < .0015). The MRSA group experienced more posttransplant complications (52% vs 19%; P < .011)), and exhibited a trend toward greater length of stay in the intensive care unit (7.8 vs 4.6 days; P = .09), but not overall length of stay. Survival was similar in MRSA and non-MRSA groups (75% vs 88%; P = .17). No significant differences in mortality were noted between liver and kidney recipients infected with MRSA (P = .6). CONCLUSION MRSA infection is associated with a higher incidence of posttransplant complications and antibiotic usage in both liver and kidney recipients compared to patients with MRSA infection.
Collapse
Affiliation(s)
- C R Schneider
- Division of Transplantation University of Cincinnati, Cincinnati, Ohio 45249, USA
| | | | | | | | | | | | | |
Collapse
|
6
|
Affiliation(s)
- M Gearhart
- HealthCare Pharmacy, Covington, OH 45318-1248, USA
| |
Collapse
|